{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:47:28Z","timestamp":1789850848360,"version":"4.0.1"},"reference-count":164,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although patients with B-cell non-Hodgkin's lymphoma (NHL) usually respond to initial conventional chemotherapy, they often relapse and mortality has continued to increase over the last three decades in spite of salvage therapy or high dose therapy and stem cell transplantation. Outcomes vary by subtype, but there continues to be a need for novel options that can help overcome chemotherapy resistance, offer new options as consolidation or maintenance therapy postinduction, and offer potentially less toxic combinations, especially in the elderly population. The bulk of these emerging novel agents for cancer treatment target important biological cellular processes. Bortezomib is the first in the class of proteasome inhibitors (PIs), which target the critical process of intracellular protein degradation or recycling and editing through the proteasome. Bortezomib is approved for the treatment of relapsed or refractory mantle cell lymphoma. The mechanisms of proteasome inhibition are very complex by nature (because they affect many pathways) and not fully understood. However, mechanisms of action shared by bortezomib and investigational PIs such as carfilzomib, marizomib, ONX-0912, and MLN9708 are distinct from those of other NHL treatments, making them attractive options for combination therapy. Preclinical evidence suggests that the PIs have additive and\/or synergistic activity with a large number of agents both in vitro and in vivo, from cytotoxics to new biologicals, supporting a growing number of combination studies currently underway in NHL patients, as reviewed in this article. The results of these studies will help our understanding about how to best integrate proteasome inhibition in the management of NHL and continue to improve patient outcomes.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-0341","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T07:17:39Z","timestamp":1336461459000},"page":"694-707","source":"Crossref","is-referenced-by-count":33,"title":["Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside"],"prefix":"10.1093","volume":"17","author":[{"given":"Anthony R.","family":"Mato","sequence":"first","affiliation":[{"name":"Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[{"name":"Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Goy","sequence":"additional","affiliation":[{"name":"Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,7]]},"reference":[{"key":"2021122308221081900_B1","first-page":"1","volume-title":"Cancer Facts & Figures 2008","author":"American Cancer Society","year":"2012"},{"key":"2021122308221081900_B2","volume-title":"SEER Stat Fact Sheets\u2013Non-Hodgkin Lymphoma","author":"National Cancer Institute"},{"key":"2021122308221081900_B3","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4065\/80.8.1087","article-title":"Non-Hodgkin lymphoma: Diagnosis and treatment","volume":"80","author":"Ansell","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"2021122308221081900_B4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"suppl 5","key":"2021122308221081900_B5","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.3816\/CLM.2007.s.021","article-title":"Expanding therapeutic options in mantle cell lymphoma","volume":"7","author":"Goy","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"2021122308221081900_B6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14656560902895715","article-title":"Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma","volume":"10","author":"Prichard","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"suppl 2","key":"2021122308221081900_B7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1634\/theoncologist.2009-S2-41","article-title":"Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: In pursuit of a complete response","volume":"14","author":"Gisselbrecht","year":"2009","journal-title":"The Oncologist"},{"key":"2021122308221081900_B8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: A suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2021122308221081900_B9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-\u03ba B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"2021122308221081900_B10","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1158\/0008-5472.CAN-06-3254","article-title":"The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines","volume":"67","author":"Strauss","year":"2007","journal-title":"Cancer Res"},{"key":"2021122308221081900_B11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/cbt.4.1.1379","article-title":"The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells","volume":"4","author":"Matta","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"2021122308221081900_B12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/sj.leu.2403400","article-title":"Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro","volume":"18","author":"Satou","year":"2004","journal-title":"Leukemia"},{"key":"2021122308221081900_B13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.onc.1208212","article-title":"Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia\/lymphoma","volume":"24","author":"Nasr","year":"2005","journal-title":"Oncogene"},{"key":"2021122308221081900_B14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2007-02-072900","article-title":"Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: An in vitro and in vivo preclinical evaluation","volume":"110","author":"Shen","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.leu.2404528","article-title":"Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma","volume":"21","author":"Bonvini","year":"2007","journal-title":"Leukemia"},{"key":"2021122308221081900_B16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"P\u00e9rez-Gal\u00e0n","year":"2006","journal-title":"Blood"},{"key":"2021122308221081900_B17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s10495-006-8048-9","article-title":"The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells","volume":"11","author":"Kabore","year":"2006","journal-title":"Apoptosis"},{"key":"2021122308221081900_B18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1080\/10428190801910912","article-title":"Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-\u03baB pathways","volume":"49","author":"Rizzatti","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122308221081900_B19","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/jnci\/djj334","article-title":"Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model","volume":"98","author":"Ishii","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2021122308221081900_B20","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1158\/1078-0432.CCR-05-0308","article-title":"The combination of the proteasome inhibitor bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide","volume":"12","author":"O'Connor","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122308221081900_B21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2010.09.051","article-title":"Radiosensitizing properties of bortezomib depend on therapeutic schedule","volume":"79","author":"Labussi\u00e8re","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308221081900_B22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00404-008-0667-7","article-title":"Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor Velcade (bortezomib, PS-341)","volume":"279","author":"Kamer","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"2021122308221081900_B23","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2007-04-084996","article-title":"Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-\u03baB regulated gene products","volume":"110","author":"Ahn","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B24","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308221081900_B25","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-06-0066","article-title":"The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia","volume":"5","author":"Ruiz","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2021122308221081900_B26","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1182\/blood-2009-09-243402","article-title":"Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia","volume":"115","author":"Roccaro","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B27","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"2021122308221081900_B28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bjc.6603406","article-title":"A novel proteasome inhibitor NPI-0052 as an anticancer therapy","volume":"95","author":"Chauhan","year":"2006","journal-title":"Br J Cancer"},{"key":"2021122308221081900_B29","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B30","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-06-0185","article-title":"Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib","volume":"5","author":"Williamson","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2021122308221081900_B31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"2021122308221081900_B32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","article-title":"NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells","volume":"110","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"2021122308221081900_B34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: Second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov Today"},{"key":"2021122308221081900_B35","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"issue":"suppl 5","key":"2021122308221081900_B36","doi-asserted-by":"crossref","first-page":"v181","DOI":"10.1093\/annonc\/mdq184","article-title":"ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Dreyling","year":"2010","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"2021122308221081900_B37","doi-asserted-by":"crossref","first-page":"v172","DOI":"10.1093\/annonc\/mdq203","article-title":"ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Tilly","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122308221081900_B38","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","article-title":"Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma","volume":"21","author":"Weigert","year":"2007","journal-title":"Leukemia"},{"key":"2021122308221081900_B39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2410.2410","article-title":"Cell based assays completed with the mantle cell lymphoma cell lines Z138 and NCEB-1 indicate that combinations of bortezomib and flavopiridol interact to achieve synergistic activity [abstract]","volume":"106","author":"Kapanen","year":"2005","journal-title":"Blood"},{"key":"2021122308221081900_B40","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2407.2407","article-title":"Combination bortezomib (PS341, Velcade) and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma [abstract]","volume":"106","author":"Wadehra","year":"2005","journal-title":"Blood"},{"key":"2021122308221081900_B41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"},{"key":"2021122308221081900_B42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/mabs.1.1.7472","article-title":"Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma","volume":"1","author":"Alinari","year":"2009","journal-title":"MAbs"},{"key":"2021122308221081900_B43","article-title":"Combined targeting of the proteasome and Bcl-2 sensitizes human B-cell lymphoma and multiple myeloma to cyclophosphamide in in vitro and in vivo models of these diseases [abstract]","volume":"104","author":"O'Connor","year":"2004","journal-title":"Blood"},{"key":"2021122308221081900_B44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2532.2532","article-title":"Inhibition of the Pan-Bcl-2 family by the small molecule GX15\u2013070 induces apoptosis in mantle cell lymphoma (MCL) cells and enhances the activity of two proteasome inhibitors (NPI-0052 and bortezomib), and doxorubicin chemotherapy [abstract]","volume":"108","author":"Yazbeck","year":"2006","journal-title":"Blood"},{"key":"2021122308221081900_B45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.832.832","article-title":"Obatoclax (GX15\u2013070) is a potent antagonist of constitutive Mcl-1\/Bak interactions in intact mitochondrial membrane and synergizes with bortezomib in mantle cell lymphoma [abstract]","volume":"108","author":"Shore","year":"2006","journal-title":"Blood"},{"key":"2021122308221081900_B46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1389.1389","article-title":"GX15\u2013070 and bortezomib induce up-regulation of BH3 single domain pro-apoptotic proteins Puma and Noxa and is associated with synergistic anti-tumor activity in rituximab-sensitive, rituximab-resistant cell lines (RSCL and RRCL), and primary lymphoma patient specimens [abstract]","volume":"110","author":"Gruber","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B47","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15\u2013070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"P\u00e9rez-Gal\u00e0n","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B48","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/leu.2008.175","article-title":"BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15\u2013070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells","volume":"22","author":"P\u00e9rez-Gal\u00e0n","year":"2008","journal-title":"Leukemia"},{"key":"2021122308221081900_B49","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2007-12-130781","article-title":"The BH3-only mimetic ABT-737 synergizes the anti-neoplastic activity of proteasome inhibitors in lymphoid malignancies","volume":"112","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"key":"2021122308221081900_B50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.827.827","article-title":"BCL6 inhibitor peptide have powerful anti-lymphoma activity in animal models of diffuse large B-cell lymphoma and synergize with other anti-lymphoma drugs [abstract]","volume":"108","author":"Antun","year":"2006","journal-title":"Blood"},{"key":"2021122308221081900_B51","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00280-009-1232-1","article-title":"The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo","volume":"66","author":"Ackler","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122308221081900_B52","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1038\/sj.onc.1206863","article-title":"Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK\/JNK- and NF-\u03baB-dependent process","volume":"22","author":"Dai","year":"2003","journal-title":"Oncogene"},{"key":"2021122308221081900_B53","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2411.2411","article-title":"Rapamycin enhances the cytotoxicity of bortezomib and rituximab on mantle cell lymphoma (MCL) cell lines [abstract]","volume":"106","author":"Ismail","year":"2005","journal-title":"Blood"},{"key":"2021122308221081900_B54","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"key":"2021122308221081900_B55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2604.2604","article-title":"The novel HDAC inhibitor UCL67022 is highly potent in multiple myeloma and non-Hodgkin's lymphoma and is enhanced by bortezomib [abstract]","volume":"108","author":"Maharaj","year":"2006","journal-title":"Blood"},{"key":"2021122308221081900_B56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3589.3589","article-title":"Histone deacetylase inhibitor (HDACi) PCI-24781 and bortezomib result in synergistic apoptosis in Hodgkin lymphoma (HL) and non-Hodgkin's lymphoma (NHL) cell lines: Investigation of cell death and NF\u03baB-mediated pathways [abstract]","volume":"110","author":"Bhalla","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma","volume":"80","author":"Heider","year":"2008","journal-title":"Eur J Haematol"},{"key":"2021122308221081900_B58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1378.1378","article-title":"Targeting histone deacetylases and unfolded protein mediated endoplasmic reticulum (ER) stress as a strategy against human mantle cell lymphoma [abstract]","volume":"110","author":"Rao","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B59","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308221081900_B60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3936.3936","article-title":"Panobinostat, a novel histone deacetylase (HiDAC) inhibitor enhances the anti-tumor activity of bortezomib (BTZ) in rituximab-chemotherapy sensitive and resistant lymphoma cell lines [abstract]","volume":"116","author":"Hernandez-Ilizaliturri","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B61","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2856.2856","article-title":"Treatment with histone deacetylase 6-specific inhibitor WT-161 disrupts hsp90 function, abrogates aggresome formation and sensitizes human mantle cell lymphoma cells to lethal ER stress induced by proteasome inhibitor carfilzomib [abstract]","volume":"116","author":"Rao","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3938.3938","article-title":"Histone deacetylase inhibitors potentiate the lethality of the irreversible proteasome inhibitor carfilzomib in mantle cell lymphoma cells in vitro and in vivo [abstract]","volume":"116","author":"Dasmahapatra","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B63","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2141.2009.07797.x","article-title":"The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor","volume":"146","author":"Paoluzzi","year":"2009","journal-title":"Br J Haematol"},{"key":"2021122308221081900_B64","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/1078-0432.CCR-10-0529","article-title":"Role of CAAT\/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells","volume":"16","author":"Rao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308221081900_B65","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4746.4746","article-title":"The proteasome inhibitor NPI-0052 in combination with bortezomib induces antitumor activity in Waldenstrom macroglobulinemia [abstract]","volume":"108","author":"Jia","year":"2006","journal-title":"Blood"},{"key":"2021122308221081900_B66","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1516.1516","article-title":"The combination of bortezomib and NPI-0052 exerts anti-tumor activity in Waldenstrom macroglobulinemia (WM) [abstract]","volume":"110","author":"Roccaro","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B67","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2517.2517","article-title":"Novel agent perifosine enhances antitumor activity of bortezomib, rituximab and other conventional therapies in Waldenstrom's macroglobulinemia [abstract]","volume":"108","author":"Leleu","year":"2006","journal-title":"Blood"},{"key":"2021122308221081900_B68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2496.2496","article-title":"The selective protein kinase CB inhibitor, enzastaurin, induces in vitro and in vivo antitumor activity in Waldenstrom's macroglobulinemia [abstract]","volume":"108","author":"Moreau","year":"2006","journal-title":"Blood"},{"key":"2021122308221081900_B69","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1535-7163.MCT-10-0238","article-title":"Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: Therapeutic implications","volume":"9","author":"Pham","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2021122308221081900_B70","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78","volume":"117","author":"Rou\u00e9","year":"2011","journal-title":"Blood"},{"key":"2021122308221081900_B71","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/cncr.23224","article-title":"Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits","volume":"112","author":"Busse","year":"2008","journal-title":"Cancer"},{"key":"2021122308221081900_B72","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2406.2406","article-title":"Active combination therapy of bortezomib (Velcade) and ibritumomab tiuxetan (Zevalin) in an in vivo diffuse large B-cell lymphoma model [abstract]","volume":"106","author":"Pervan","year":"2005","journal-title":"Blood"},{"key":"2021122308221081900_B73","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4049\/jimmunol.178.3.1923","article-title":"Selective inhibition of I\u03baB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level","volume":"178","author":"Rou\u00e9","year":"2007","journal-title":"J Immunol"},{"key":"2021122308221081900_B74","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2005.05656.x","article-title":"Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death","volume":"130","author":"Georgakis","year":"2005","journal-title":"Br J Haematol"},{"key":"2021122308221081900_B75","doi-asserted-by":"crossref","first-page":"5528s","DOI":"10.1158\/1078-0432.CCR-07-0982","article-title":"Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2","volume":"13","author":"Smith","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122308221081900_B76","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"2021122308221081900_B77","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06908.x","article-title":"A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: Long-term follow-up in newly diagnosed mantle cell lymphoma","volume":"140","author":"Evens","year":"2008","journal-title":"Br J Haematol"},{"key":"2021122308221081900_B78","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"2021122308221081900_B79","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B80","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B81","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B82","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdh093","article-title":"Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: Results of a phase II study","volume":"15","author":"Jermann","year":"2004","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"2021122308221081900_B83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.2009-S2-17","article-title":"Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: A review of the evidence","volume":"14","author":"Morschhauser","year":"2009","journal-title":"The Oncologist"},{"key":"2021122308221081900_B84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1034\/j.1600-0609.2002.01692.x","article-title":"Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: A phase II study","volume":"69","author":"J\u00e4eger","year":"2002","journal-title":"Eur J Haematol"},{"key":"2021122308221081900_B85","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B86","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"key":"2021122308221081900_B87","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B88","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B89","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B90","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cncr.22097","article-title":"Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"107","author":"Faderl","year":"2006","journal-title":"Cancer"},{"key":"2021122308221081900_B91","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122308221081900_B92","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B93","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122308221081900_B94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","article-title":"Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial","volume":"145","author":"O'Connor","year":"2009","journal-title":"Br J Haematol"},{"key":"2021122308221081900_B95","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3109\/10428194.2010.483302","article-title":"Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial","volume":"51","author":"Goy","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2021122308221081900_B96","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.411.411","article-title":"Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies [abstract]","volume":"110","author":"Alsina","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B97","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.409.409","article-title":"Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: Phase 1 results [abstract]","volume":"110","author":"Orlowski","year":"2007","journal-title":"Blood"},{"issue":"15 suppl","key":"2021122308221081900_B98","article-title":"Phase I study of the novel proteasome inhibitor NPI-0052 in patients with lymphoma and solid tumors","volume":"26","author":"Aghajanian","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B99","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma","volume":"117","author":"Baiocchi","year":"2011","journal-title":"Cancer"},{"key":"2021122308221081900_B100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","article-title":"Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstr\u00f6m macroglobulinaemia","volume":"151","author":"Agathocleous","year":"2010","journal-title":"Br J Haematol"},{"key":"2021122308221081900_B101","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3965.3965","article-title":"Weekly infusion of bortezomib in combination with rituximab in relapsed\/refractory indolent non-follicular and mantle cell lymphoma is safe and effective: Two-years analysis of phase II trial BRIL06 of Intergruppo Italiano Linfomi (IIL) [abstract]","volume":"116","author":"Chiappella","year":"2010","journal-title":"Blood"},{"issue":"15 suppl","key":"2021122308221081900_B102","article-title":"A phase II trial of bortezomib plus lenalidomide for relapsed\/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis","volume":"28","author":"Morrison","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B102a","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/10428194.2011.608445","article-title":"A phase I study evaluating ibritumomab tiuxetan (Zevalin\u00ae) in combination with bortezomib (Velcade\u00ae) in relapsed\/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma","volume":"53","author":"Beaven","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"18 suppl","key":"2021122308221081900_B103","article-title":"A phase I trial of PS-341 and fludarabine for relapsed and refractory indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"24","author":"Snell","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B104","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma\u2014long-term results of a multicenter observation study","volume":"50","author":"Weigert","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2021122308221081900_B105","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10428194.2010.546015","article-title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)","volume":"52","author":"Kouroukis","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2021122308221081900_B106","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2141.2009.07998.x","article-title":"Fludarabine, bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma","volume":"148","author":"Orciuolo","year":"2010","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2021122308221081900_B107","article-title":"A pilot study with rituximab, bortezomib and hyper-fractionated cyclophosphamide (RBC regimen) for the treatment of advanced mantle cell lymphoma in elderly patients","volume":"93","author":"Musto","year":"2008","journal-title":"Haematologica"},{"key":"2021122308221081900_B108","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3708.3708","article-title":"Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed\/refractory indolent and mantle cell lymphomas [abstract]","volume":"114","author":"Gerecitano","year":"2009","journal-title":"Blood"},{"key":"2021122308221081900_B109","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"2021122308221081900_B110","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2578.2578","article-title":"Bortezomib, rituximab, and dexamethasone (BORID) as salvage treatment in relapsed\/refractory mantle cell lymphoma: Sustained disease control in patients achieving a complete remission [abstract]","volume":"110","author":"Drach","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B111","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2791.2791","article-title":"Final results of the RiPAD+C regimen including Velcade in front line therapy for elderly patients with mantle cell lymphoma. A phase II prospective study of the GOELAMS group [abstract]","volume":"116","author":"Gressin","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B112","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3051.3051","article-title":"Phase I trial of bortezomib in combination with rituximab-hyperCVAD\/methotrexate and cytarabine for untreated mantle cell lymphoma [abstract]","volume":"112","author":"Romaguera","year":"2008","journal-title":"Blood"},{"key":"2021122308221081900_B113","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2010.08315.x","article-title":"Phase I trial of bortezomib in combination with rituximab-hyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma","volume":"151","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"2021122308221081900_B114","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.265.265","article-title":"VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: A phase II study from the Wisconsin oncology network [abstract]","volume":"112","author":"Kahl","year":"2008","journal-title":"Blood"},{"key":"2021122308221081900_B115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2569.2569","article-title":"A phase 1 trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15\u2013070) in combination with bortezomib in patients with relapsed\/refractory mantle cell lymphoma [abstract]","volume":"110","author":"Goy","year":"2007","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122308221081900_B116","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.07.003","article-title":"Treatment of follicular non-Hodgkin's lymphoma: The old and the new","volume":"45","author":"Friedberg","year":"2008","journal-title":"Semin Hematol"},{"key":"2021122308221081900_B117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00063030-200620010-00002","article-title":"Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas","volume":"20","author":"Paoluzzi","year":"2006","journal-title":"BioDrugs"},{"key":"2021122308221081900_B118","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","article-title":"Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma","volume":"115","author":"Di Bella","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B119","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.768.768","article-title":"Final results of a randomized phase 2 multicenter study of two bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA) study FL-05 [abstract]","volume":"116","author":"Ribrag","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B120","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1078-0432.CCR-08-2647","article-title":"Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes","volume":"16","author":"O'Connor","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308221081900_B121","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"Vos","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B122","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","article-title":"Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial","volume":"12","author":"Coiffier","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308221081900_B123","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.265.265","article-title":"Identification of patient subgroups demonstrating longer progression-free survival (PFS) benefit with bortezomib-rituximab versus rituximab in patients with relapsed or refractory follicular lymphoma (FL): biomarker analyses of the phase 3 LYM3001 study [abstract]","volume":"118","author":"Coiffier","year":"2011","journal-title":"Blood"},{"issue":"15 suppl","key":"2021122308221081900_B124","article-title":"A randomized, open-label, multicenter phase II study of bortezomib with fludarabine in comparison to rituximab with fludarabine in follicular lymphoma subjects previously treated with rituximab","volume":"28","author":"Theocharous","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B125","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1749.1749","article-title":"Bortezomib may be safely combined with y-90 ibritumomab tiuxetan in patients with relapsed\/refractory follicular or transformed non-Hodgkin lymphoma: A phase I trial of combined induction therapy and bortezomib consolidation [abstract]","volume":"116","author":"Roy","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B126","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2141.2009.07836.x","article-title":"Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"147","author":"Barr","year":"2009","journal-title":"Br J Haematol"},{"key":"2021122308221081900_B127","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.924.924","article-title":"Bendamustine, bortezomib and rituximab in patients (pts) relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): A multicenter phase II clinical trial [abstract]","volume":"114","author":"Friedberg","year":"2009","journal-title":"Blood"},{"key":"2021122308221081900_B128","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","article-title":"Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study","volume":"29","author":"Fowler","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B129","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2798.2798","article-title":"Bortezomib in combination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma: Results of a phase 2 study [abstract]","volume":"116","author":"Craig","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B130","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2010.33.6594","article-title":"Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"29","author":"Sehn","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B131","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1200\/JCO.2011.35.5586","article-title":"Is there a role for bortezomib combinations in the management of patients with follicular lymphoma?","volume":"29","author":"Salles","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B132","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1769.1769","article-title":"Bortezomib (Velcade), rituximab, cyclophosphamide, dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active in elderly patient population [abstract]","volume":"116","author":"Nabhan","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B133","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B134","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"26","author":"Fu","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B135","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3324\/haematol.2010.038109","article-title":"Survival impact of rituximab combined with ACVBP and upfront consolidative autotransplantation in high risk diffuse large B-cell lymphoma for GELA","volume":"96","author":"Fitoussi","year":"2011","journal-title":"Haematologica"},{"key":"2021122308221081900_B136","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1200\/JCO.2006.05.5897","article-title":"Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma","volume":"24","author":"Imhoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B137","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3109\/10428194.2011.588761","article-title":"Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy","volume":"52","author":"Hong","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2021122308221081900_B138","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-\u03baB-dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B139","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1385.1385","article-title":"Phase I\/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma [abstract]","volume":"104","author":"Dunleavy","year":"2004","journal-title":"Blood"},{"key":"2021122308221081900_B140","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.4446.4446","article-title":"A phase I trial of bortezomib plus CHOP every 2 weeks in patients with advanced stage diffuse large B-cell lymphomas [abstract]","volume":"110","author":"Jang","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B141","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122308221081900_B142","article-title":"Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"25","author":"Mounier","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B143","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"2021122308221081900_B144","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1792.1792","article-title":"Rapid prospective identification of non-germinal center B cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) patients for targeted trials: Early results from PYRAMID, a phase 2 randomized study of R-CHOP \u00b1 bortezomib in newly diagnosed non-GCB DLBCL [abstract]","volume":"116","author":"Doner","year":"2010","journal-title":"Blood"},{"key":"2021122308221081900_B145","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B146","article-title":"Phase II trial of combination of bortezomib and rituximab in relapsed and\/or refractory Waldenstrom macroglobulinemia [abstract]","volume":"112","author":"Ghobrial","year":"2008","journal-title":"Blood"},{"key":"2021122308221081900_B147","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308221081900_B148","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2005.2005","article-title":"Phase I results of combination gemcitabine and bortezomib (Velcade\u00ae) for relapsed\/refractory nodal T-cell non-Hodgkin lymphoma (T-NHL) and aggressive B-cell NHL (B-NHL) [abstract]","volume":"112","author":"Evens","year":"2008","journal-title":"Blood"},{"key":"2021122308221081900_B149","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2466.2466","article-title":"Cutaneous T cell lymphoma: Responses in phase 1 trial of combination therapy with liposomal doxorubicin, bortezomib, and gemcitabine [abstract]","volume":"108","author":"Dhillon","year":"2006","journal-title":"Blood"},{"issue":"15 suppl","key":"2021122308221081900_B150","article-title":"A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial","volume":"27","author":"Delmer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B151","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B152","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308221081900_B153","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1399-3062.2009.00411.x","article-title":"Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: A comprehensive review of reported cases","volume":"11","author":"Styczynski","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"2021122308221081900_B154","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1128\/JVI.02241-06","article-title":"Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells","volume":"81","author":"Zou","year":"2007","journal-title":"J Virol"},{"key":"2021122308221081900_B155","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/156800911794519725","article-title":"Second generation proteasome inhibitors: Carfilzomib and immunoproteasome-specific inhibitors (IPSIs)","volume":"11","author":"Kuhn","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"2021122308221081900_B156","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","article-title":"Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors","volume":"113","author":"Kuhn","year":"2009","journal-title":"Blood"},{"key":"2021122308221081900_B157","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2146\/ajhp070272","article-title":"Bortezomib: A novel chemotherapeutic agent for hematologic malignancies","volume":"65","author":"Utecht","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"2021122308221081900_B158","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/14796694.4.2.149","article-title":"Bortezomib in mantle cell lymphoma","volume":"4","author":"Suh","year":"2008","journal-title":"Future Oncol"},{"key":"2021122308221081900_B159","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2559.2559","article-title":"Preliminary results of a phase I\/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenstrom's macroglobulinaemia [abstract]","volume":"110","author":"Agathocleous","year":"2007","journal-title":"Blood"},{"key":"2021122308221081900_B160","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1574.1574","article-title":"Weekly treatment with a combination of bendamustine and bortezomib in relapsed or refractory indolent non-Hodgkin's lymphoma: A single-center phase 1\/2 study [abstract]","volume":"112","author":"Moosmann","year":"2008","journal-title":"Blood"},{"key":"2021122308221081900_B161","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308221081900_B162","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308221081900_B163","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0341","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/5\/694\/41859286\/oncolo_17_5_694.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/5\/694\/41859286\/oncolo_17_5_694.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T09:23:01Z","timestamp":1713950581000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/5\/694\/6403361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":164,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,7]]},"published-print":{"date-parts":[[2012,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0341","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,5,1]]},"published":{"date-parts":[[2012,5,1]]}}}